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Background
The Lipo5 lipopeptides included in the ANRS vaccine tri-
als have been initially designed on the basis of the immu-
nodominant CD8+ T cell epitopes but have been shown
to induce both CD4+ and CD8+ T cell response in healthy
vaccinees. In order to characterize the CD4+ T cell
response specific for the Lipo5 sequences, we derived
Lipo5 specific T cell lines using in vitro stimulation and
characterized their specificity.
Methods
Specific CD4+ T cell responses were induced in vitro
against Lipo5 peptides on 8 HLA unrelated naive donors.
Purified CD4+ T cells were stimulated once a week during
4 weeks, by mature DC loaded with Lipo5 peptides. The
CD4+ T cell response was revealed by IFN-γ ELISpots.
Results
All 8 donors developed an important specific CD4+ T cell
response. Globally, we found a mean of 32 specific CD4+
precursors per twenty million of peripheral CD4+ T cells.
Fifty seven per cent of the Lipo5-specific response was
against Gag 253–284, 150 T cell lines being specific for
this peptide. T cell response specific for Pol 325–355, Gag
17–35, Nef 116–154 and Nef 66–97 represented 21%,
11%, 6% and 5% of the Lipo5 specific response, respec-
tively. In agreement with its binding capacity, we demon-
strated that the strong immunogenicity of Gag 253–284
was due to its presentation by multiple HLA DR mole-
cules. All the 51 specific CD4+ T cell lines, with the excep-
tion of two, were stimulated by the clade B and C
consensus sequences.
Conclusion
In agreement with the observations made in vaccinees,
Lipo5 sequences introduced in the ANRS vaccine elicit a
strong CD4+ T cell response in vitro and contain multiple
CD4 epitopes. We therefore confirmed the good immu-
nogenicity of the Lipo5 peptides and demonstrated their
capacity to elicit a multiepitopic CD4+ response cross
reacting with clade B and C sequences.
from AIDS Vaccine 2009
Paris, France. 19–22 October 2009
Published: 22 October 2009
Retrovirology 2009, 6(Suppl 3):P300 doi:10.1186/1742-4690-6-S3-P300
<supplement> <title> <p>AIDS Vaccine 2009</p> </title> <editor>Anna Laura Ross</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S3-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf</url> </supplement>
This abstract is available from: http://www.retrovirology.com/content/6/S3/P300
© 2009 Castelli et al; licensee BioMed Central Ltd. 